Hello board. Longish time(April 2020) reader and f

Hello board. Longish time(April 2020) reader and first time poster.
I find it interesting that this study can get so little reaction -share price/board interest in various other places--- vs. what CYDY board would do/think with same results.
From release:
"Death occurred in 0% (n=0/13) of mavrilimumab-treated patients by Day 28, compared to 27% (n=7/26) of control-group patients (p=0.086)."
"Mavrilimumab was well-tolerated in all patients, without infusion reactions." I know about the long term Adverse effects, but we are looking at an acute use situation with a single administered dose.

I find it difficult to filter the noise, obvious shorters/bashers, silly cheerleading (?pumping?) so I ask what would we do/what would we expect share price to do if our results are published with these results.
FYI I am long CYDY and will remain so until reasons to sell exhibit themselves-poor data/insider selling/lack of medical consensus etc.

Cheers!